Caribou Biosciences (CRBU) Change in Receivables (2020 - 2026)
Caribou Biosciences (CRBU) reported Change in Receivables of $158000.0 for Q1 2026, up 189.27% year-over-year from $54621.1 in Q1 2025, and up 191.33% quarter-over-quarter from -$173000.0 in Q4 2025.
Caribou Biosciences (CRBU) Change in Receivables (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Change in Receivables data on file, last reported at $158000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at $158000.0, up 189.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $139000.0 (up 109.89% YoY), and the FY2025 annual result was -$196000.0, up 57.21% from the prior year.
- Change in Receivables climbed to $158000.0 in Q1 2026 per CRBU's latest filing, from -$173000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $1.7 million in Q3 2023 and troughed at -$2.1 million in Q2 2023.
- A 5-year average of -$224588.2 and a median of -$173000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables plunged 1674.32% in 2022, then jumped 517.97% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$485000.0 in 2022, then tumbled by 103.09% to -$985000.0 in 2023, then jumped by 114.72% to $145000.0 in 2024, then plunged by 219.31% to -$173000.0 in 2025, then soared by 191.33% to $158000.0 in 2026.
- Business Quant data shows CRBU's Change in Receivables at $158000.0 in Q1 2026, -$173000.0 in Q4 2025, and -$152000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | 158,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -1.33 Mn |
| Jun 30, 2024 | -1.33 Mn |
| Mar 31, 2024 | 770,000.00 |
| Mar 31, 2024 | 770,000.00 |
| Dec 31, 2023 | -985,000.00 |
| Dec 31, 2023 | -985,000.00 |